Synairgen Regulatory News (SNG)

Synairgen plc

('Synairgen' or the 'Company')

Board Change

Southampton, UK - 5 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on 31 December 2024.

With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001.

The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.

Simon Shaw, Chairman of the Board of Synairgen, said: "On behalf of the Board and the team at Synairgen, I would like to express my thanks to Phill for his significant contribution over many years, particularly for progressing the early-stage clinical development of SNG001. We wish him the very best for the future."

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com